Sugi Predict

Sugi Predict / Compounds / SCHEMBL1635368

SCHEMBL1635368

SCHEMBL1635368

CO[C@@H]1CCN(c2ccc3c(C(=O)O)nn(COCC[Si](C)(C)C)c3c2)C1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 4/20 0.35
▸ NAPEPLD Q6IQ20 1/20 0.34
▸ NTSR1 P30989 3/20 0.34
▸ IDH1 O75874 2/20 0.33
▸ PRKAB2 O43741 2/20 0.33
▸ PRKAG1 P54619 2/20 0.33
▸ PRKAA2 P54646 2/20 0.33
▸ PRKAA1 Q13131 2/20 0.33
▸ PRKAG3 Q9UGI9 2/20 0.33
▸ PRKAG2 Q9UGJ0 2/20 0.33
▸ PRKAB1 Q9Y478 2/20 0.33
▸ ACACB O00763 2/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.33
▸ SCD O00767 2/20 0.33
▸ SCD5 Q86SK9 2/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ KLKB1 P03952 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635287 1.00 USP30 (0.35) USP30NAPEPLDNTSR1IDH1PRKAB2
SCHEMBL1636053 0.93 NTSR1 (0.35) USP30NAPEPLDNTSR1IDH1PRKAB2
SCHEMBL1968817 0.93 NTSR1 (0.35) USP30NAPEPLDNTSR1IDH1PRKAB2
SCHEMBL492426 0.93 NTSR1 (0.35) USP30NAPEPLDNTSR1IDH1PRKAB2
SCHEMBL1965894 0.82 LOXL2 (0.40) NTSR1PRKAG1PRKAA1PRKAB1KLKB1
SCHEMBL1962999 0.81 LIPG (0.40) ACACBFFAR4
SCHEMBL1965446 0.78 DGAT1 (0.36) KLKB1
SCHEMBL1966579 0.77 EGLN1 (0.37) ACACB
SCHEMBL492499 0.75 DGAT1 (0.40) —
SCHEMBL1965595 0.75 KHK (0.37) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932248-B2 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity MEMORY PHARMACEUTICALS CORPORATION (US) 2011-04-26 — — US disclosed
US-20070135417-A1 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity MEMORY PHARMACEUTICALS CORPORATION 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135417-A1 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity CHRNA7, CHRNA5, CHRNA3 USP30 4009/4885NAPEPLD 1382/4885NTSR1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.